tiprankstipranks
Trending News
More News >

Neuren Pharmaceuticals Updates on Securities Buy-Back Program

Story Highlights
Neuren Pharmaceuticals Updates on Securities Buy-Back Program

Confident Investing Starts Here:

Neuren Pharmaceuticals Limited ( (AU:NEU) ) has provided an announcement.

Neuren Pharmaceuticals Limited announced an update on its ongoing buy-back program, reporting a total of 3,837,460 securities bought back prior to the previous day, with an additional 33,732 securities repurchased on the previous day. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.

The most recent analyst rating on (AU:NEU) stock is a Buy with a A$31.40 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.

More about Neuren Pharmaceuticals Limited

Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders. The company’s primary products are aimed at addressing unmet medical needs in this specialized market.

Average Trading Volume: 741,578

Technical Sentiment Signal: Buy

Current Market Cap: A$1.74B

For detailed information about NEU stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App